SCHEMBL20733586

SCHEMBL20733586

C[C@@]1(O)[C@@H](COC(=O)c2ccccc2)O[C@@H](n2ccc3c(Cl)ncnc32)[C@@H]1O

nearest known ligand 0.61

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 20/20 0.61
WDR77 Q9BQA1 20/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29392290 0.84 PRMT5 (0.43) PRMT5WDR77
SCHEMBL20738551 0.84 PRMT5 (0.43) PRMT5WDR77
SCHEMBL20721480 0.84 PRMT5 (0.43) PRMT5WDR77
SCHEMBL31123788 0.83 PRMT5 (0.42) PRMT5WDR77
SCHEMBL25109992 0.82 PRMT5 (0.41) PRMT5WDR77
SCHEMBL30003625 0.82 PRMT5 (0.41) PRMT5WDR77
SCHEMBL31123838 0.81 PRMT5 (0.60) PRMT5WDR77
SCHEMBL23535874 0.81 PRMT5 (0.60) PRMT5WDR77
SCHEMBL22663625 0.79 PRMT5 (0.72) PRMT5WDR77
SCHEMBL20721544 0.78 PRMT5 (0.84) PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220160713-A1 SELECTIVE INHIBITOR OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) WILMINGTON PHARMATECH COMPANY, LLC 2022-05-26 US disclosed
US-20220152072-A1 Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) PRELUDE THERAPEUTICS, INCORPORATED 2022-05-19 US disclosed
US-20220153747-A1 Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) PRELUDE THERAPEUTICS, INCORPORATED 2022-05-19 US disclosed
EP-3939986-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) Prelude Therapeutics, Incorporated (US) 2022-01-19 EP disclosed
US-11208416-B2 Selective inhibitors of protein arginine methytransterase 5 (PRMT5) PRELUDE THERAPEUTICS INCORPORATED (US) 2021-12-28 US disclosed
US-11078205-B2 Selective inhibitors of protein arginine methlytransferase 5 (PRMT5) PRELUDE THERAPEUTICS, INCORPORATED (US) 2021-08-03 US disclosed
EP-3665179-B1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRELUDE THERAPEUTICS INC (US) 2021-06-09 EP disclosed
US-20200361946-A1 Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) PRELUDE THERAPEUTICS INC (US) 2020-11-19 US disclosed
WO-2020206289-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 PRELUDE THERAPEUTICS, INCORPORATED (US) 2020-10-08 WO disclosed
US-20200148692-A1 Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) PRELUDE THERAPEUTICS INC (US) 2020-05-14 US disclosed
US-10570140-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRELUDE THERAPEUTICS INCORPORATED (US) 2020-02-25 US disclosed
WO-2019032859-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRELUDE THERAPEUTICS, INCORPORATED (US) 2019-02-14 WO disclosed
US-20190048014-A1 Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) PRELUDE THERAPEUTICS INCORPORATED 2019-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11078205-B2 Selective inhibitors of protein arginine methlytransferase 5 (PRMT5) PRMT5, PRMT1, PRMT3 PRMT5 1/4885WDR77 142/4885
US-20200148692-A1 Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) PRMT5, PRMT1, PRMT6 PRMT5 1/4885WDR77 283/4885
US-20220152072-A1 Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) PRMT5, PRMT1, PRMT6 PRMT5 1/4885WDR77 76/4885
US-11208416-B2 Selective inhibitors of protein arginine methytransterase 5 (PRMT5) PRMT5, PRMT1, PRMT6 PRMT5 1/4885WDR77 283/4885
US-20220160713-A1 SELECTIVE INHIBITOR OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRMT5, PRMT1, PRMT6 PRMT5 1/4885WDR77 153/4885
US-20220153747-A1 Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) PRMT5, PRMT1, PRMT6 PRMT5 1/4885WDR77 283/4885
US-10570140-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRMT5, PRMT1, PRMT6 PRMT5 1/4885WDR77 87/4885
US-20190048014-A1 Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) PRMT5, PRMT1, PRMT6 PRMT5 1/4885WDR77 87/4885
US-20200361946-A1 Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) PRMT5, PRMT1, PRMT6 PRMT5 1/4885WDR77 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.